In the group of patients with RA, the presence of a D2T population in 34.3%, the suspension of MTX, and the presence of monotherapy in 54.8% of patients reduced the percentage of patients treated with anti-TNF biosimilars (24.3%). This evidence concerns the gene TNF and rheumatoid arthritis.